Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

AnBogen Therapeutics

Tracked across 15 events · 123 articles · First seen Jan 17, 2026 · Last active Sep 08, 2026

Sentiment
40
Attention
7
Events
15
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Tech
Impact: AnBogen Therapeutics announced two key research abstracts for its lead compound, Imofinostat (ABT-301), demonstrating its potential in enhancing immunotherapy for colorectal cancer and overcoming chemotherapy resistance in pancreatic cancer. The company is also advancing a Phase 1/2 clinical trial and plans for an Emerging Stock Market listing.
Apr 13, 2026 · 6 articles
3 70
Business
Impact: AnBogen Therapeutics engaged two consulting firms to advance its lead candidate, PT-00114, into Phase 2 clinical studies, which is expected to strengthen its operational processes and regulatory strategy.
May 19, 2026 · 6 articles
2 10
Business
Impact: AnBogen Therapeutics will participate in two investment bank conferences, providing an opportunity to present its pipeline and potentially attract investor interest.
May 28, 2026 · 6 articles
1 10
Business
Impact: AnBogen Therapeutics granted inducement awards to three new employees, consisting of stock options and restricted stock units, as a material inducement for their employment. This action aims to attract and retain talent, which is generally positive for the company's long-term prospects.
Jun 16, 2026 · 6 articles
2 60
Business
Impact: Cyllene raised €33M Series C, rebranded, and advanced EG110A clinical development, positioning for Phase 2b/3 study in 2027.
Jul 07, 2026 · 6 articles
2 80
Business
Impact: Vistagen is the target of the stake acquisition. The investment and potential engagement could lead to strategic changes, boosting its stock price and providing validation for its pipeline.
Aug 04, 2026 · 6 articles
0 0
Business
Impact: Protagonist granted inducement awards to new employees, reflecting ongoing talent acquisition. The company's pipeline includes ICOTYDE and rusfertide, with regulatory milestones ahead.
Aug 04, 2026 · 9 articles
2 30
Regulatory
Impact: AnBogen Therapeutics is the developer of PT00114 and the recipient of FDA's pre-IND feedback. This positive regulatory milestone supports its clinical development plans and may enhance its market position, though the company still faces substantial financial and clinical risks.
Aug 20, 2026 · 6 articles
2 20
Business
Impact: Anbogen is the primary company initiating the collaboration to advance its lead drug candidate ABT-301. The agreement could support clinical development and potentially increase the company's valuation.
Jul 20, 2026 · 6 articles
2 60
Business
On September 8, 2026, AnBogen Therapeutics announced that its Board of Directors authorized a share repurchase program of up to $300 million of its outstanding common stock. The company plans to fund the repurchases using…
Impact: Protagonist is the company authorizing the $300 million share repurchase, funded by its cash and collaboration payments. This action signals financial strength and commitment to returning capital to shareholders, likely positively impacting its stock.
Sep 08, 2026 · 7 articles
4 90
Regulatory
Impact: Protagonist receives $275 million in payments and up to $875 million more plus royalties, boosting its financial independence and funding its pipeline. Its stock has nearly tripled over the past year.
Aug 28, 2026 · 6 articles
7 65
Tech
Impact: AnBogen Therapeutics, a wholly-owned subsidiary of the Menarini Group, announced new data related to elacestrant and tagraxofusp at the 2026 ASCO Annual Meeting, and its partner Karyopharm Therapeutics presented data on selinexor.
May 25, 2026 · 33 articles
2 40
Business
Impact: Founding investor and development partner; CEO Ivar Hakonarson becomes Chairman of Synaptiq.
Jul 23, 2026 · 6 articles
2 0
Business
Jan 17, 2026 · 6 articles
4 0
Tech
Jun 14, 2026 · 8 articles
100 AnBogen Therapeutics authorized share repurchaseProtagonist Therapeutics...
ERGEN INTELLIGENCE
Track AnBogen Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.